- Home
- MCRB vs DLHC Comparison
MCRB vs DLHC Comparison
Compare MCRB & DLHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- DLHC
- Stock Information
- Founded
- MCRB 2010
- DLHC 1969
- Country
- MCRB United States
- DLHC United States
- Employees
- MCRB N/A
- DLHC N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- DLHC Business Services
- Sector
- MCRB Health Care
- DLHC Consumer Discretionary
- Exchange
- MCRB Nasdaq
- DLHC Nasdaq
- Market Cap
- MCRB 72.0M
- DLHC 74.2M
- IPO Year
- MCRB 2015
- DLHC N/A
- Fundamental
- Price
- MCRB $7.63
- DLHC $5.51
- Analyst Decision
- MCRB Hold
- DLHC
- Analyst Count
- MCRB 4
- DLHC 0
- Target Price
- MCRB $73.67
- DLHC N/A
- AVG Volume (30 Days)
- MCRB 75.0K
- DLHC 46.8K
- Earning Date
- MCRB 08-12-2025
- DLHC 07-30-2025
- Dividend Yield
- MCRB N/A
- DLHC N/A
- EPS Growth
- MCRB N/A
- DLHC 75.08
- EPS
- MCRB 8.98
- DLHC 0.38
- Revenue
- MCRB N/A
- DLHC $377,074,000.00
- Revenue This Year
- MCRB N/A
- DLHC N/A
- Revenue Next Year
- MCRB N/A
- DLHC N/A
- P/E Ratio
- MCRB $0.89
- DLHC $14.52
- Revenue Growth
- MCRB N/A
- DLHC N/A
- 52 Week Low
- MCRB $6.53
- DLHC $2.72
- 52 Week High
- MCRB $30.60
- DLHC $11.99
- Technical
- Relative Strength Index (RSI)
- MCRB 48.66
- DLHC 63.84
- Support Level
- MCRB $7.25
- DLHC $5.32
- Resistance Level
- MCRB $7.89
- DLHC $5.66
- Average True Range (ATR)
- MCRB 0.46
- DLHC 0.24
- MACD
- MCRB 0.11
- DLHC -0.03
- Stochastic Oscillator
- MCRB 60.23
- DLHC 72.60
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About DLHC DLH Holdings Corp.
DLH Holdings Corp is a provider of technology-enabled business process outsourcing and program management solutions in the United States. The company offers services to several government agencies which include the Department of Veteran Affairs. The company is engaged in public health, performance evaluation, and health operations to solve the complex problems faced by civilian and military customers alike, leveraging digital transformation, artificial intelligence, analytics, cloud-based applications, telehealth systems, and others.